-
Product Insights
NewNet Present Value Model: Stoke Therapeutics Inc’s Zorevunersen Sodium
Empower your strategies with our Net Present Value Model: Stoke Therapeutics Inc's Zorevunersen Sodium report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Childhood Epilepsy – Drugs In Development, 2023
Global Markets Direct’s, ‘Childhood Epilepsy - Drugs In Development, 2023’, provides an overview of the Childhood Epilepsy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Childhood Epilepsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) – Drugs In Development, 2023
Global Markets Direct’s, ‘Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Drugs In Development, 2023’, provides an overview of the Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
NewNet Present Value Model: Stoke Therapeutics Inc’s STK-001
Empower your strategies with our Net Present Value Model: Stoke Therapeutics Inc's STK-001 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MVXONCO-1 in Head And Neck Cancer Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MVXONCO-1 in Head And Neck Cancer Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.MVXONCO-1 in Head And Neck Cancer Squamous Cell...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Zorevunersen Sodium in Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zorevunersen Sodium in Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Zorevunersen Sodium in Dravet Syndrome (Severe Myoclonic...
-
Company Insights
Innovation and Patenting activity of Stoke Therapeutics Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Stoke Therapeutics Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Sector Analysis
Dravet Syndrome (DS) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Dravet Syndrome (DS) Marketed and Pipeline Drugs Report Overview Dravet syndrome is also known as severe myoclonic epilepsy of infancy (SMEI). It is a rare and severe form of epilepsy that typically begins in the first year of life. The exact cause of Dravet syndrome is usually genetic. However, seizures in affected individuals can be triggered by various factors including fever, infections, and sometimes vaccinations. These triggers can lead to prolonged and potentially life-threatening seizures known as status epilepticus. Genetic...
-
Product Insights
Net Present Value Model: STK-001
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model STK-001 Drug Details STK-001 is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – STK-001
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry STK-001 Drug Details STK-001 is under development for the treatment of Dravet syndrome. It...